Hidden

AN INTRAVAGINAL RING FOR THE TREATMENT OF TYPE II DIABETES

Approximately 12.6 million or 10.8% of all American women aged 20 years or older have diabetes. GLP-1 agonists such as exenatide are very valuable tools in the treatment of diabetes. Currently, these drugs are administered as daily or weekly injections. Many women do not prefer injections which leads to non-compliance and eventually, higher healthcare costs. Based on several analyst reports, we believe that the GLP-1 agonist market is greater than $4 billion in annual sales. Auritec Pharmaceuticals has formulated a GLP-1 agonist intravaginal ring (IVR) which may improve compliance and ease of use in Type II Diabetic women. This IVR has been tested in vitro and in vivo and has shown sustained-release for 2-4 weeks. It is being further developed for a first-in-human clinical trial.

IN VITRO RELEASE DATA IN BIO-RELEVANT MEDIA

IN VIVO RELEASE DATA IN SHEEP